Atrial fibrillation (AF) is an increasingly common cause of stroke and systemic embolism.
While warfarin has been the mainstay of stroke prevention in patients with AF, newer novel …

Rivaroxaban (Xarelto®), a direct factor Xa inhibitor, is approved for the prevention of stroke
and systemic embolism in patients with atrial fibrillation (AF) in Canada or those with …

Atrial fibrillation (AF) is the most common cardiac arrhythmia in the developed world and is
associated with a fivefold increase in the risk of stroke, accounting for up to 15% of strokes in …

BACKGROUND: Atrial fibrillation (AF), the most common significant cardiac arrhythmia,
increases the risk of stroke, particularly in the elderly. Warfarin is effective in reducing stroke …

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it leads to
significant morbidity and mortality, predominantly from ischemic stroke. Vitamin K …

In the majority of patients with non-valvular atrial fibrillation (AF) anticoagulation is required
to reduce the risk of stroke. Although vitamin K antagonists effectively reduce the risk of …

Oral anticoagulation is the mainstay of therapy for stroke prevention in patients with atrial
fibrillation (AF). Vitamin K antagonists such as warfarin have many drawbacks that reduce …

Introduction: Registries and non-interventional studies offer relevant and complementary
information to clinical trials, since they have a high external validity. Areas covered: The …

Background Atrial fibrillation (AF), the most common cardiac arrhythmia, is a major risk factor
for stroke. Rivaroxaban, an oral factor Xa inhibitor, is approved for the prevention of stroke in …

Rivaroxaban is a direct factor Xa inhibitor that is widely available to reduce the risk of stroke
or systemic embolism in patients with nonvalvular atrial fibrillation and one or more risk …